Alcohol use disorder: An analysis of the evidence underpinning clinical practice guidelines
- PMID: 35063840
- PMCID: PMC8885851
- DOI: 10.1016/j.drugalcdep.2022.109287
Alcohol use disorder: An analysis of the evidence underpinning clinical practice guidelines
Abstract
Background: As Clinical Practice Guidelines (CPGs) provide effective guidance for providing medical care for individuals with alcohol use disorder (AUD), the evidence behind them should be robust.
Objective: Our primary objective was to critically appraise the methodological and reporting quality of systematic reviews cited within CPGs regarding the treatment of AUD. Our secondary objective was to determine how frequently Cochrane Reviews were cited as justification and to evaluate appraisals between Cochrane and non-Cochrane reviews.
Methods: We searched PubMed to identify CPGs for the treatment of AUD published between 2015 and 2021. Systematic reviews included in each CPG were evaluated using the Preferred Reporting Instrument for Systematic Reviews and Meta-Analyses (PRISMA) and a validated quality assessment tool (AMSTAR-2). Additional study characteristics were recorded.
Results: From the screening process, 98 systematic reviews from 6 CPGs met inclusion criteria. PRISMA adherence ranged from 72% to 85% (mean of 79%). AMSTAR-2 adherence ranged from 52% to 73% (mean of 68%). AMSTAR appraisal ratings found 32 (35.6%) critically low, 10 (11.1%) low, 35 (38.9%) moderate, and only 13 (14.4%) high systematic reviews. Cochrane systematic reviews displayed greater PRISMA (0.92 vs. 0.75: p < 0.001) and AMSTAR-2 (0.90 vs. 0.61.; p < 0.001) scores compared to the non-Cochrane studies.
Conclusion: Systematic reviews included in CPGs for AUD treatment showed variable adherence to PRISMA and AMSTAR-2 guidelines, with almost half of the systematic reviews being critically low to low methodological quality. Given the prevalence of alcohol use disorder, methodological and reporting quality recommendations are important to strengthening evidence informing CPGs.
Keywords: AMSTAR; Alcohol-use disorder; Clinical Practice Guidelines; Evidence-Based Medicine; PRISMA; Systematic Review Methodology.
Copyright © 2022 Elsevier B.V. All rights reserved.
References
-
- Alcohol Use Disorder Methodological Quality, 2021.
-
- Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD, GRADE Working Group, 2016. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 353, i2016. - PubMed
-
- Als-Nielsen B, Chen W, Gluud C, Kjaergard LL, 2003. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 290, 921–928. - PubMed
-
- Amato L, Minozzi S, Vecchi S, Davoli M, 2010. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst. Rev. CD005063. - PubMed
-
- American Psychiatric Association, 2018. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder, Practice Guidelines. American Psychiatric Association Publishing.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
